An investigational extended-release (ER) formulation of amantadine hydrochloride (ADS-5102, Adamas Pharmaceuticals) led to a statistically significant reduction in levodopa-induced dyskinesia (LID) ...

Despite these co-formulations, Levodopa carries significant risk of side-effects, including dyskinesia. As a result, despite its effectiveness in reducing motor symptoms associated with Parkinson’s ...

For patients with Parkinson's disease (PD) who have levodopa-induced dyskinesia (LID), amantadine can maintain its antidyskinetic effect over several years, a new study indicates. The finding goes ...

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's Disease GENEVA, Switzerland, November 4, 2010 /PRNewswire/ -- Merck ...

The FDA has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine extended-release capsules; Adamas) for the treatment of levodopa-induced dyskinesia (LID) in patients with ...

WARSAW, Poland, March 04, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, ...

Adamas announced positive long-term data from the Phase 3 EASE LID 2 trial which evaluated Gocovri (amantadine extended-release) in Parkinson’s disease patients with dyskinesia on levodopa-based ...

Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease (Logo: http ...

Strong Late Stage Contender ADS-5102 Targets Debilitating Condition. IPO and Milestone Payments Put Adamas in a Favorable Cash Position. IPO Lock-up Period Expired in October 2014. Several years ago, ...

GOTHENBURG, SE / ACCESSWIRE / January 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson's disease, today announced the top-line ...

- IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses “When it comes to Parkinson’s disease, the community is ...